Business Context and Reporting Period
This Form 8-K is filed by TRxADE HEALTH, INC. (noting the metadata reference to Scienture Holdings appears to be an error, as the filing explicitly names TRxADE HEALTH, INC.) on October 17, 2022. The report addresses Item 8.01 (Other Events) concerning the company's compliance status with The Nasdaq Stock Market LLC listing requirements.
Key Financial Metrics
The filing does not provide a comprehensive set of financial metrics such as revenue, profit, or cash flow. However, it discloses the following specific figures related to listing compliance:
- Stockholders' Equity (Q2 2022): $1,804,533 (reported in the Form 10-Q for the quarter ended June 30, 2022).
- Nasdaq Minimum Requirement: $2,500,000.
- Recent Capital Raise: $1.75 million from the public sale of common stock (or pre-funded warrants) completed on October 7, 2022.
- Concurrent Private Placement: Warrants to purchase up to 2,663,045 shares of common stock.
Material Changes and Events
The primary material event is the company's failure to meet the Nasdaq Capital Market minimum stockholders' equity requirement. On July 29, 2022, the company received a deficiency notice. Although the company submitted a compliance plan by the September 12, 2022 deadline, it has not yet formally evidenced compliance. On October 17, 2022, Nasdaq granted an extension to regain compliance.
Outlook, Risks, and Management Commentary
Compliance Extension Terms: The company must complete specific transactions by January 25, 2023, to regain compliance. This includes the recently completed $1.75 million sale and potentially other actions. The company must then file a public report evidencing compliance via one of two alternatives (actual compliance or pro forma adjustments).
Risks: If the company fails to evidence compliance in its next periodic SEC filing, it may be subject to delisting. Management notes that while they are accounting for the recent transactions which may result in compliance, there is no guarantee they will meet the rule even after the offering.
Management Stance: The company states it is confident it can regain compliance within the granted timeframe and is pursuing various other potential courses of action.
Investor Verification Checklist
- Verify the final accounting impact of the $1.75 million public sale and the concurrent private placement of warrants on the company's stockholders' equity.
- Monitor the next periodic SEC filing (10-Q or 10-K) to confirm if the company has formally evidenced compliance with Nasdaq Rule 5550(b)(1).
- Assess the risk of delisting if the company fails to meet the January 25, 2023 deadline or fails to demonstrate compliance in the subsequent filing.
- Confirm the exact number of shares issued in the October 7, 2022 transaction to evaluate potential dilution.